Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).

导出 LinkOut

翻译打印收藏纠错

第一作者： Michael J,Morris

作者： Michael J,Morris ; Jose Mauricio,Mota ; Kristine,Lacuna ; Patrick,Hilden ; Martin,Gleave ; Michael A,Carducci ; Fred,Saad ; Erica D,Cohn ; Julie,Filipenko ; Glenn,Heller ; Neal,Shore ; Andrew J,Armstrong ; Howard I,Scher

关键词 Biochemical recurrence Castration sensitive Docetaxel Nonmetastatic Prostate cancer Rising prostate-specific antigen

主题词雄激素拮抗药(Androgen Antagonists);雄激素类(Androgens);人类(Humans);男(雄)性(Male);前列腺肿瘤(Prostatic Neoplasms);生活质量(Quality of Life)

DOI 10.1016/j.euo.2021.04.008

PMID 34020931

发布时间 2024-09-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

European urology oncology

2021年4卷4期

543-552页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).

European urology oncology

相似文献

European urology oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).

European urology oncology

相似文献

European urology oncology

相关期刊

检索历史清除